vendredi 27 juillet 2012

Press Review (July 28, 2012) – Revue de presse (28 juillet 2012)





Cancer Drug May Flush Out 'Hidden' HIV: Study‎‎
Strategy could help battle 'reservoir' of germs, but research is in early stages.
By Randy Dotinga. In U.S. News & World Report

Brittany Wenger, 17, Wins Google Science Fair Grand Prize For Breast Cancer Diagnosis App‎‎‎
Have you ever helped the hard-of-hearing listen to music? Or built a computer program to diagnose breast cancer? These kids have.
By Dino Grandoni. In Huffington Post

Pregnancy post 30 lowers cancer risk‎‎
Women who last give birth at age 40 or older have a 44 per cent decreased risk of endometrial cancer when compared to women who have their last birth under the age of 25, a new study has revealed.
In Times of India

Antioxidants Might Help Cut Pancreatic Cancer Risk, Study Suggests‎ ‎‎
But the research cannot prove cause and effect, and better trials are needed, experts say.
In U.S. News & World Report

New York State passes legislation to help improve breast cancer detection‎
The National Cancer Institute estimates in 2012 there will be 226,870 new cases of breast cancer in women with 39,510 deaths. In response to a need to improve breast cancer detection and prevention Governor Andrew M. Cuomo signed legislation on July 23, 2012 that requires mammography services to inform patients if dense breast tissue is found during an exam.
By Harold Mandel. In The Examiner

Should cancer be kept secret?‎‎
Some hide life-threatening illnesses from friends and family, but suffer guilt.
By Leanne Italie. In Salon

FDA Approves Everolimus (Afinitor) for Metastatic Breast Cancer‎
The US Food and Drug Administration (FDA) approved the mTOR inhibitor everolimus (Afinitor) last week for use in postmenopausal women with HER2-negative, hormone-receptor–positive advanced breast cancer patients. Afinitor was approved in combination with exemestane(Drug information on exemestane) (Aromasin) in those patients whose cancer progressed following treatment with letrozole or anastrozole.
By Anna Azvolinsky. In Cancer Network

New biomarker for common lung cancer predicts responses to chemotherapy‎‎‎‎
Patients with the most common type of lung cancer are notoriously insensitive to chemotherapy drugs, including cisplatin. New findings related to the cellular pathways that regulate responses to cisplatin have now been published by Cell Press on July 26th in the journal Cell Reports. The findings reveal a potential biomarker that can be used to predict how these patients will respond to chemotherapy, as well as the patients' overall prognosis, paving the way for personalized treatment strategies
In EurekAlert (press release)


Limiter le sel pour diminuer le risque de cancer de l'estomac‎‎ ‎‎
Un organisme anglais de prévention du cancer alerte sur l'impact d'une alimentation trop salée, qui favorise le risque de tumeur à l'estomac.
Par Romy Raffin. Dans Le Figaro

Cancer du pancréas : découverte d'un processus qui bloquerait les métastases‎
Des scientifiques du centre de recherche en cancérologie de Marseille (CRCM) ont annoncé avoir identifié un processus cellulaire au sein des tumeurs pancréatiques qui permettrait de bloquer la formation de métastases. Une découverte porteuse d'espoir pour ce cancer trop souvent mortel.
Dans MaxiSciences

Un médicament contre le cancer pour débusquer le VIH‎
Une catégorie de médicaments couramment employés dans le traitement du cancer permettrait de débusquer le VIH-sida lorsqu'il se cache sous forme latente dans le sang des malades, affirment des chercheurs américains.
Dans Radio-Canada.com

Le bronzage en spray pourrait causer des cancers et de l'infertilité‎
Bronzer est définitivement une activité risquée. Après les cabines de bronzage, soupçonnées d'augmenter les risques de cancer, c'est au tour des autobronzants d'être pointés du doigt par la recherche, rapporte The Telegraph.
Dans Slate.fr


Aucun commentaire:

Enregistrer un commentaire